UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 19, 2017

CV SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	**000-54677**	**80-0944970**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2688 South Rainbow Boulevard, Suite B
Las Vegas, Nevada 89146
(Address of principal executive offices, Zip Code)

(866) 290-2157
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On June 19, 2017, CV Sciences, Inc. (the "Company") announced the results of its "pre-IND" meeting with the U.S. Food and Drug Administration (FDA) held on June 15, 2017. A copy of this announcement is attached hereto as Exhibit 99.1 and incorporated herein by reference solely for purposes of this Item 7.01 disclosure.

The Company also announced that on June 15, 2017 the Securities and Exchange Commission filed a Complaint against the Company and the Company's President and Chief Executive Officer, as more particularly described in Item 8.01 of this Current Report on Form 8-K. A copy of this announcement is attached hereto as Exhibit 99.2 and incorporated herein by reference solely for purposes of this Item 7.01 disclosure.

Exhibits 99.1 and 99.2 each contain forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.

The information set forth under Item 7.01 of this Current Report on Form 8-K ("Current Report"), including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 8.01 Other Events

On June 19, 2017, the Company learned that on June 15, 2017, the Securities and Exchange Commission (the "SEC") filed a Complaint against the Company and Michael Mona, Jr., the Company's President and Chief Executive Officer. The Complaint alleges that the Company's financial reporting of its acquisition of certain assets from PhytoSphere Systems, LLC in 2013 (the "Transaction") was improper, and constitutes fraud. More specifically, the SEC contends that the Company's quarterly reports on Form 10-Q for the first three quarters of 2013 improperly reported the Transaction. The SEC bases its claims against the Company and Mr. Mona on the position that the Company's reporting of the Transaction in 2013, and prior to its restatement of those financial reports in April 2014, overstated the value of the Company's assets.

The Complaint alleges that Mr. Mona personally benefitted from the alleged fraud by receiving a holiday bonus of $10,000 in December 2013.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1	Press Release, dated June 19, 2017.
99.2	Press Release, dated June 19, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 20, 2017

CV SCIENCES, INC.

By: /s/ Michael Mona, Jr.
Michael Mona, Jr.
President and Chief Executive Officer

Exhibit 99.1

CV SCIENCES, INC. ANNOUNCES COMMENCEMENT OF IND PREPARATION IMMEDIATELY FOLLOWING PRE-IND MEETING WITH FDA

LAS VEGAS, NV – (Marketwired – June 19, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the "Company," "CV Sciences," "our" or "we"), today announced that it held its pre-IND meeting with the U.S. Food and Drug Administration (FDA) on June 15, 2017, to review its drug development plan for CVSI-007, the Company's patent-pending product for smokeless tobacco addiction therapy consisting of nicotine-polacrilex chewing gum in combination with synthetic cannabidiol (CBD).

CV Sciences President and CEO Michael J. Mona, Jr. commented, "Our pre-IND meeting with the FDA was very constructive and provided the Company with a favorable development roadmap for this important combination drug candidate. We have immediately commenced preparation of our Investigational New Drug application (IND) to initiate human trials. Our New Drug Application will be under the 505(b)2 pathway using nicotine-polacrilex gum, an FDA-approved nicotine replacement therapy, as our referenced listed drug. While nicotine-polacrilex gum is one of several approved nicotine replacement therapies for smoking tobacco addiction, all forms of nicotine replacement therapy have failed to achieve success in smokeless tobacco addiction. The FDA confirmed that it does not consider CBD to be a New Chemical Entity. We explained our scientific rationale for the addition of CBD to nicotine replacement therapies, based on our own proprietary research and peer-reviewed literature showing evidence of CBD inhibition of several different molecular pathways known to be important in treating nicotine addiction. We are extremely excited to advance this program in developing an effective therapy for one of the most addictive and potent ways of consuming nicotine, affecting 300 million users worldwide and 9 million users in the U.S."

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:
Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

Exhibit 99.2

CV Sciences, Inc.'s CEO Releases Letter to Stockholders and Customers Regarding Complaint filed by Securities and Exchange Commission

June 19, 2017

LAS VEGAS, NV – (Marketwired - June 19, 2017) - CV Sciences, Inc. (OTCQB: CVSI), (the "Company," "CV Sciences," "our" or "we"), today released a letter from Michael Mona, Jr., Chief Executive Officer, to stockholders and customers regarding a recent complaint filed by the Securities and Exchange Commission (the "SEC"):

Dear Stockholders and Customers,

First, thank you for your continued support of and belief in our Company. As you may be aware, on June 15, 2017, the SEC filed a complaint against our Company and me personally, alleging fraud in making misrepresentations and/or misleading omissions on our quarterly reports filed with the SEC in 2013. We owe it to our stockholders and customers to respond to this complaint.

The complaint relates to our acquisition of the assets of PhytoSphere Systems, LLC in January 2013. The key asset purchased in the transaction was the seller's European inventory supply chain, which is the asset critical in launching our successful consumer products division. In its complaint, the SEC does not question the legality of the transaction nor does the SEC criticize our operations. Further, the SEC does not suggest that any officer or director sold shares of stock in connection with this transaction, or at any other time. The SEC simply takes issue with how the Company reported the transaction in its quarterly reports to the SEC during the first three quarters of 2013. More specifically, with the benefit of hindsight, the SEC takes issue with the negotiated acquisition price and the timing of our valuation to determine asset reporting value.

The Company stands behind the PhytoSphere transaction and its financial reporting during 2013. We have retained Paul Hastings as our litigation counsel and intend to vigorously defend this matter.

We have positive news on several aspects of operations. Last week, we met with the U.S. Food & Drug Administration regarding the development of our patent-pending drug candidate in treating smokeless tobacco addiction. The FDA meeting resulted in a favorable development road map for this important drug candidate. More details are provided in the Company's press release today.

Also, our industry-leading consumer products division continues to perform extremely well. Customer support and acceptance of our products is evidenced by placement in nearly 1,200 retail locations throughout the U.S.

My intention with this letter is to ensure that our stockholders and customers have accurate information regarding the SEC matter discussed above and the potential for both divisions of our Company. We stand behind our Company, our employees, our customers and our products, and are proud of what we have accomplished to date. We continue to work hard to become the industry-leading developer of CBD-based products for both the consumer and prescription drug market.

Michael J. Mona, Jr.
President & CEO
CV Sciences, Inc.

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:
Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784